Medpace shares jumped over 16% after Q2 results showed 17.2% revenue growth for the quarter ended June 30, 2026. The company also raised/confirmed full-year 2026 guidance, reinforcing a positive outlook and driving the stock move.
Medpace shares jumped over 16% after Q2 results showed 17.2% revenue growth for the quarter ended June 30, 2026. The company also raised/confirmed full-year 2026 guidance, reinforcing a positive outlook and driving the stock move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
